+86-27-65522453 sales@sun-shinechem.com

SRT1720

Catalog No.: 52007
Cas No.: 1001645-58-4
Purity : 98% 
52007 - SRT1720 | CAS 1001645-58-4

Catalog number : 52007

CAS number : 1001645-58-4

分子式 : C25H23N7OS.HCl 

分子量 : 506.02 

Iupac 化学名称 : N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide hydrochloride 

Smile : O=C(C1=NC2=CC=CC=C2N=C1)NC3=CC=CC=C3C4=CN5C(SC=C5CN6CCNCC6)=N4.[H]Cl

InChiKey : DTGRRMPPXCRRIM-UHFFFAOYSA-N

PackagingPriceAvailabilityPurityEstimated Shipping Time
BulkEnquiryEnquiry
Request Bulk Quote Download MSDS电话:+86-27-65522453 | Email:sales@sun-shinechem.com
同义词SRT1720,SRT-1720,SRT 1720 
英文同义词SRT1720,SRT-1720,SRT 1720 
分子式C25H23N7OS.HCl 
分子量506.02 
外观yellow solid,being red exposed in air. 
纯度98% 
可溶性2mg/ml in DMSO 
存储3 years -20ºCpowder 
运输条件Shipped under ambient temperature 
SmileO=C(C1=NC2=CC=CC=C2N=C1)NC3=CC=CC=C3C4=CN5C(SC=C5CN6CCNCC6)=N4.[H]Cl
InChiKeyDTGRRMPPXCRRIM-UHFFFAOYSA-N
InChiInChI=1S/C25H23N7OS.ClH/c33-24(22-13-27-20-7-3-4-8-21(20)28-22)29-19-6-2-1-5-18(19)23-15-32-17(16-34-25(32)30-23)14-31-11-9-26-10-12-31;/h1-8,13,15-16,26H,9-12,14H2,(H,29,33);1H

SRT1720 is a selective SIRT1 activator with EC50 of 0.16 M, but is >230-fold less potent for SIRT2 and SIRT3. SRT1720(SRT-1720) is an experimental drug that was studied by Sirtris Pharmaceuticals intended as a small-molecule activator of the sirtuin subtype SIRT1. The compound has been studied in animals, but safety and efficacy in humans have not been established. 

1. Tyler J. Lahusen and Chu-Xia Deng, SRT1720 Induces Lysosomal-Dependent Cell Death of Breast Cancer Cells. Cancer Biology and Signal Transduction DOI: 10.1158/1535-7163.MCT-14-0584 Published January 2015

 

Abstract:

SRT1720 is an activator of SIRT1, a NAD+-dependent protein and histone deacetylase that plays an important role in numerous biologic processes. Several studies have illustrated that SRT1720 treatment could improve metabolic conditions in mouse models and in a study in cancer SRT1720 caused increased apoptosis of myeloma cells. However, the effect of SRT1720 on cancer may be complex, as some recent studies have demonstrated that SRT1720 may not directly activate SIRT1 and another study showed that SRT1720 treatment could promote lung metastasis. To further investigate the role of SRT1720 in breast cancer, we treated SIRT1 knockdown and control breast cancer cell lines with SRT1720 both in vitro and in vivo. We showed that SRT1720 more effectively decreased the viability of basal-type MDA-MB-231 and BT20 cells as compared with luminal-type MCF-7 breast cancer cells or nontumorigenic MCF-10A cells. We demonstrated that SRT1720 induced lysosomal membrane permeabilization and necrosis, which could be blocked by lysosomal inhibitors. In contrast, SRT1720-induced cell death occurred in vitro irrespective of SIRT1 status, whereas in nude mice, SRT1720 exhibited a more profound effect in inhibiting the growth of allograft tumors of SIRT1 proficient cells as compared with tumors of SIRT1-deficient cells. Thus, SRT1720 causes lysosomal-dependent necrosis and may be used as a therapeutic agent for breast cancer treatment. Mol Cancer Ther; 14(1); 183–92. ©2014 AACR.


1001645-58-4 - Request Bulk Quote

×
1001645-58-4 - Request Bulk Quote
Change